Cargando…

Abstract 153: Examination of the affinity of anti-SARS-CoV-2 IgA, which is mucosal immunity, for SARS-CoV-2 BA.4 variant and BA.5 variant

Detalles Bibliográficos
Autores principales:	Hayashi, Takuma, Yaegashi, Nobuo, Konishi, Ikuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society for Biochemistry and Molecular Biology, Inc. Published by Elsevier Inc. 2023
Materias:	Topic Category Protein Synthesis, Structure, Modifications and Interactions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100299/ http://dx.doi.org/10.1016/j.jbc.2023.103981

Ejemplares similares

Abstract 1997: Assembling a structural model of the SARS-CoV-2 replication and transcription complex from 60+ subunits
por: Perry, Jason
Publicado: (2023)

Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer
por: Hayashi, Takuma, et al.
Publicado: (2022)

Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1
por: Geng, Qibin, et al.
Publicado: (2022)

Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals
por: Hayashi, Takuma, et al.
Publicado: (2020)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Abstract 1390: Multiplex measurements of the impacts of ACE2 sequence and cell surface abundance during SARS-like coronavirus entry
por: Shukla, Nidhi, et al.
Publicado: (2023)

Possibility of SARS-CoV-2 Infection in the Metastatic Microenvironment of Cancer
por: Hayashi, Takuma, et al.
Publicado: (2022)

Cancer therapy with decreased SARS-CoV-2 infection rates in cancer patients
por: Hayashi, Takuma, et al.
Publicado: (2021)

Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
por: Evans, John P., et al.
Publicado: (2022)

Tumor Necrosis Factor-α Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2)
por: Lambert, Daniel W., et al.
Publicado: (2005)

Differences in environmental stability among SARS-CoV-2 variants of concern: both omicron BA.1 and BA.2 have higher stability
por: Hirose, Ryohei, et al.
Publicado: (2022)

Introduction, Spread and Impact of the SARS-CoV-2 Omicron Variants BA.1 and BA.2 in Cyprus
por: Richter, Jan, et al.
Publicado: (2022)

Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab
por: Fujita, Shigeru, et al.
Publicado: (2022)

Evolution of SARS-CoV-2: BA.4/BA.5 Variants Continues to Pose New Challenges
por: Quadir, Neha, et al.
Publicado: (2022)

Noneffect of SARS-CoV-2 spike glycoprotein Y217N mutation on affinity between the virus and ACE2
por: Hayashi, Takuma, et al.
Publicado: (2021)

Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants
por: Zheng, Qianqian, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant
por: Saito, Akatsuki, et al.
Publicado: (2022)

Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark
por: Lyngse, Frederik Plesner, et al.
Publicado: (2022)

Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission
por: Shrestha, Lok Bahadur, et al.
Publicado: (2022)

Implications of the SARS-CoV-2 subvariants BA.4 and BA.5
por: Rahimi, Farid, et al.
Publicado: (2022)

Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5
por: Wang, Yanqun, et al.
Publicado: (2023)

Abstract 1385: An evolutionary divergent thermodynamic brake in ZAP-70 fine-tunes the kinetic proofreading in T cells
por: Gangopadhyay, Kaustav, et al.
Publicado: (2023)

Abstract 1382: Visualization and functional annotation of coronavirus spike protein glycoshields
por: Hsu, Shang-Te Danny, et al.
Publicado: (2023)

Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
por: Kumar, Sanjeev, et al.
Publicado: (2022)

Regional Replacement of SARS-CoV-2 Variant Omicron BA.1 with BA.2 as Observed through Wastewater Surveillance
por: Boehm, Alexandria B., et al.
Publicado: (2022)

Strain wars 5: Gibbs energies of binding of BA.1 through BA.4 variants of SARS-CoV-2
por: Popovic, Marko
Publicado: (2022)

High-resolution melting analysis to discriminate between the SARS-CoV-2 Omicron variants BA.1 and BA.2
por: Koshikawa, Takuro, et al.
Publicado: (2022)

Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2
por: Golcuk, Mert, et al.
Publicado: (2022)

Differences in Presentation of SARS-CoV-2 Omicron Strain Variant BA.1–BA.5 Peptides by HLA Molecules
por: Nersisyan, S. A., et al.
Publicado: (2023)

Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
por: Wong, Carlos K H, et al.
Publicado: (2023)

Ablation of CD8(+) T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3
por: Swaminathan, Srividhya, et al.
Publicado: (2022)

Estimating the serial intervals of SARS‐CoV‐2 Omicron BA.4, BA.5, and BA.2.12.1 variants in Hong Kong
por: Guo, Zihao, et al.
Publicado: (2023)

Commentary on ‘Implications of the SARS-CoV-2 subvariants BA.4 and BA.5’
por: Khani, Elnaz, et al.
Publicado: (2023)

Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant
por: Qu, Panke, et al.
Publicado: (2022)

Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant
por: Qu, Panke, et al.
Publicado: (2022)

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants
por: Fujimoto, Kana, et al.
Publicado: (2022)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2022)

Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2
por: Yang, Yang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g78vtl58bmj6hjnprqtroe1knc